Common Contracts

EX-10.32 4 dex1032.htm MEMBERS AGREEMENT CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] MEMBERS AGREEMENT

Distribution and Assignment Agreement • May 5th, 2020 • Delaware

• Contract Type
  Distribution and Assignment Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

This Members Agreement (this “Agreement”) is made effective as of the 1st day of January, 2008, by and among Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Square, Cambridge, Massachusetts 02142 (“Genzyme”); BioMarin Pharmaceutical Inc., a Delaware corporation having its principal place of business at 105 Digital Drive, Novato, California 94949 (“BioMarin”); BioMarin Genetics, Inc., a Delaware corporation and a wholly-owned subsidiary of BioMarin having its principal place of business at 105 Digital Drive, Novato, California 94949 (“BioMarin Subsidiary”); and BioMarin/Genzyme LLC, a Delaware limited liability company having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (the “Company”), of which BioMarin, BioMarin Subsidiary and Genzyme are the only members. Genzyme, BioMarin, BioMarin Subsidiary and the Company are sometimes referred to herein individually as a “Party” and collectively as th

CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] MEMBERS AGREEMENT

Distribution and Assignment Agreement • February 28th, 2008 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Distribution and Assignment Agreement
• Filed
  February 28th, 2008
• Company
  Biomarin Pharmaceutical Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This Members Agreement (this “Agreement”) is made effective as of the 1st day of January, 2008, by and among Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Square, Cambridge, Massachusetts 02142 (“Genzyme”); BioMarin Pharmaceutical Inc., a Delaware corporation having its principal place of business at 105 Digital Drive, Novato, California 94949 (“BioMarin”); BioMarin Genetics, Inc., a Delaware corporation and a wholly-owned subsidiary of BioMarin having its principal place of business at 105 Digital Drive, Novato, California 94949 (“BioMarin Subsidiary”); and BioMarin/Genzyme LLC, a Delaware limited liability company having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (the “Company”), of which BioMarin, BioMarin Subsidiary and Genzyme are the only members. Genzyme, BioMarin, BioMarin Subsidiary and the Company are sometimes referred to herein individually as a “Party” and collectively as th